Autopsy report · NCT02070406
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
Cause of deathSlow enrollment
“low accrual”
Life of this trial
- Registered 5 months before it started.
- Ran for about 4 years 5 months before it stopped.
- 4 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Jonsson Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cyclophosphamide; fludarabine phosphate; NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL; dendritic cell vaccine therapy; aldesleukin; fludeoxyglucose F 18
- Participants
- 4
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.